About The Study:

Menstrual migraines, also known as hormone headaches, happen right before or during a woman’s period – up to two days before the start of your period through the first three days of your period. Menstrual migraines are very prevalent and affect 25% or more in women with migraines and may get worse with movement, light, smells, or sound lasting from a few hours to several days.  

Menstrual Migraine attacks are considered more difficult to treat compared with migraine attacks at other times of the month, are more disabling, tend to last longer, and have a higher tendency to recur. Therefore, there is a dire need for an approved treatment to address those who suffer from menstrual migraines.  

Rochester Clinical Research is currently conducting a research study designed to evaluate whether Ubrogepant, an FDA-approved medication for the acute treatment of migraine in adults, is effective when taken preventively for Menstrual migraine attacks. With its known efficacy in the acute treatment of migraine, when administered before or during the headache phase, and with its favorable safety and tolerability profile, Ubrogepant use could offer a new preventive treatment option to patients with Menstrual migraines. 

The study lasts about 20 months (about 1 and a half years) and includes a 16 week (about 3 and a half months) screening period (to include 3 menstrual cycles, a 16 week double blind treatment period (where the patient does not know if they will receive Ubrogepant or placebo, and then a one year (52 week) open label where all patients will receive Ubrogepant for each cycle and as needed for other attacks.  

Qualifications

  • Must be 18 years or older
  • At least one year history of migraine with or without aura
  • Experienced migraine attacks in at least 2 of the last 3 PMPs
  • *Please note, other conditions may apply.